Protocol to establish a genetically engineered mouse model of IDH1-mutant astrocytoma

被引:1
|
作者
Shi, Diana D. [1 ,2 ]
Lee, Joyce H. [3 ]
Wang, Adam C. [3 ]
Khanal, Januka [3 ]
Gao, Wenhua [3 ]
Kaelin Jr, William G. [3 ,4 ]
Mcbrayer, Samuel K. [2 ,5 ,6 ]
机构
[1] Harvard Med Sch, Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA 02115 USA
[2] Univ Texas Southwestern Med Ctr Dallas, Childrens Med Ctr Res Inst, Dallas, TX 75390 USA
[3] Harvard Med Sch, Dana Farber Canc Inst, Brigham & Womens Hosp, Dept Med Oncol, Boston, MA USA
[4] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA
[5] Univ Texas Southwestern Med Ctr Dallas, Dept Pediat, Dept Pediat, Dallas, TX 75390 USA
[6] Univ Texas Southwestern Med Ctr Dallas, Harold C Simmons Comprehens Canc Ctr, Dallas, TX 75235 USA
来源
STAR PROTOCOLS | 2023年 / 4卷 / 02期
关键词
Cancer; Model Organisms; Neuroscience;
D O I
10.1016/j.xpro.2023.102281
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Lower-grade gliomas exhibit a high prevalence of isocitrate dehydrogenase 1 (IDH1) mutations, but faithful models for studying these tumors are lacking. Here, we present a protocol to establish a genetically engineered mouse (GEM) model of grade 3 astrocytoma driven by the Idh1R132H oncogene. We describe steps for breeding compound transgenic mice and intracranially delivering adeno-associated virus particles, followed by post-surgical surveillance via magnetic resonance imaging. This protocol enables the generation and use of a GEM to study lower-grade IDH-mutant gliomas.For complete details on the use and execution of this protocol, please refer to Shi et al. (2022).1
引用
收藏
页数:17
相关论文
共 50 条
  • [1] Metabolic Landscape of a Genetically Engineered Mouse Model of IDH1 Mutant Glioma
    Ruiz-Rodado, Victor
    Seki, Tomohiro
    Dowdy, Tyrone
    Lita, Adrian
    Zhang, Meili
    Han, Sue
    Yang, Chunzhang
    Cherukuri, Murali K.
    Gilbert, Mark R.
    Larion, Mioara
    CANCERS, 2020, 12 (06) : 1 - 12
  • [2] Comparative survey of mitochondrial ultrastructure in IDH1-mutant astrocytoma and IDH1-wildtype glioblastoma (GBM)
    Maraqah, Haitham H.
    Abu-Asab, Mones S.
    Lee, Han Sung
    Aboud, Orwa
    ULTRASTRUCTURAL PATHOLOGY, 2023, 47 (02) : 116 - 121
  • [3] CREATION OF A GENETICALLY ENGINEERED MOUSE MODEL OF ANAPLASTIC ASTROCYTOMA DRIVEN BY THE IDH1R132H ONCOGENE
    Shi, Diana
    Wang, Adam
    Gao, Wenhua
    Khanal, Januka
    Levitt, Michael
    Jennings, Rebecca
    Bonal, Dennis
    Signoretti, Sabina
    Quang-De Nguyen
    Cahill, Daniel
    Abdullah, Kalil
    Ligon, Keith
    Kaelin, William
    McBrayer, Samuel
    NEURO-ONCOLOGY, 2020, 22 : 230 - 231
  • [4] IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity
    Khurshed, Mohammed
    Aarnoudse, Niels
    Hulsbos, Renske
    Hira, Vashendriya V. V.
    van Laarhoven, Hanneke W. M.
    Wilmink, Johanna W.
    Molenaar, Remco J.
    van Noorden, Cornelis J.
    FASEB JOURNAL, 2019, 33
  • [5] IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity
    Khurshed, Mohammed
    Aarnoudse, Niels
    Hulsbos, Renske
    Hira, Vashendriya V. V.
    van Laarhoven, Hanneke W. M.
    Wilmink, Johanna W.
    Molenaar, Remco J.
    van Noorden, Cornelis J. F.
    FASEB JOURNAL, 2018, 32 (11): : 6344 - 6352
  • [6] Ivosidenib for IDH1-mutant cholangiocarcinoma
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2020, 5 (07): : 647 - 647
  • [7] Ivosidenib effective in IDH1-mutant AML
    Peter Sidaway
    Nature Reviews Clinical Oncology, 2018, 15 : 472 - 472
  • [8] Ivosidenib for advanced IDH1-mutant cholangiocarcinoma
    Gervaso, Lorenzo
    Pellicori, Stefania
    Fazio, Nicola
    LANCET ONCOLOGY, 2020, 21 (08): : E370 - E370
  • [9] Spikes induced by IDH1-mutant gliomas
    Abounader, Roger
    Wright, Karen
    Bhat, Krishna
    Chamberlain, Marc
    Purow, Benjamin
    Soffietti, Riccardo
    NEURO-ONCOLOGY, 2017, 19 (10) : 1295 - 1296
  • [10] Ivosidenib effective in IDH1-mutant AML
    Sidaway, Peter
    NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (08) : 472 - 472